Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

NCT04904276 · clinicaltrials.gov ↗
TERMINATED
Status
16
Enrollment
INDUSTRY
Sponsor class

Stopped met minimum enrollment goal, however, enrollment was slow due to the pandemic, therefore, the study was terminated

Conditions

Interventions

Sponsor

Rigel Pharmaceuticals